Q3 2025 · 13F-HR
BIOS Capital Management, LPholdings as filed
Filed 2025-11-12 · accession 0001104659-25-110482
$88.9M
Reported value
6
Positions
2025-09-30
Period end
The Brief · BIOS Capital Management, LP · Q3 2025
AI · grounded in 13F
BIOS Capital Management, LP established a new position in ACTU valued at $67.2M. The fund also initiated stakes in CGTX for $8.1M and IRD for $6.6M. Additional new positions include LTRN, RNTX, and INABEUR.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 005083100 | ACTU | ACTUATE THERAPEUTICS INC | $67.2M | 75.6% | 10,049,996 | Common | SHARED |
| 19243B102 | CGTX | COGNITION THERAPEUTICS INC | $8.1M | 9.11% | 6,000,000 | Common | SHARED |
| 67577R102 | IRD | OPUS GENETICS INC | $6.6M | 7.42% | 3,683,429 | Common | SHARED |
| 51654W101 | LTRN | LANTERN PHARMA INC | $4.4M | 4.97% | 1,015,715 | Common | SHARED |
| 00887A204 | RNTX | REIN THERAPEUTICS INC | $1.9M | 2.19% | 1,690,751 | Common | SHARED |
| 45674E109 | INABEUR | IN8BIO INC | $622,061 | 0.70% | 286,664 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.